Experts discuss HIIT as an underused ‘disease-modifying drug’ for inflammatory diseases. Learn how to safely integrate it into patient treatment plans.
                                
                                Experts discuss HIIT as an underused ‘disease-modifying drug’ for inflammatory diseases. Learn how to safely integrate it into patient treatment plans.
                                CPPD diagnosis is difficult & treatments are limited. Experts review radiology challenges, off-label options like colchicine, & emerging biologics.
                                Richard F. Loeser, Jr., MD, MACR, delivering the Oscar Gluck Memorial Lecture at ACR Convergence 2025, discussed research into new treatments for osteoarthritis.
                                Why do lymphatics fail in inflammatory arthritis? Research from ACR Convergence 2025 points to a network of telocytes & mast cells that control synovial drainage.
                                At ACR Convergence 2025, Joan T. Merrill, MD, overviewed the current research landscape of chimeric antigen receptor (CAR) T cell therapies for systemic lupus erythematosus (SLE), raising important scientific questions about these emerging treatments.
                                At this ACR Convergence 2025 session, immunologist Dusan Bogunovic, PhD, discussed his team’s research into how genetic immune diseases manifest with different phenotypes in different people.
In this episode, Dr. Kumar talks about the insidious nature of ageism and how rheumatologists can combat it.
Pediatric rheumatologic diseases are characterized by high rates of anxiety & depression known to impact health-related outcomes. CARRA and the ACR developed guidance statements to assess & manage mental health concerns for youths in pediatric rheumatology practice.
Learn how to identify & combat age-based discrimination for improved communication & better patient outcomes.